anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Older patients with spinal cord injury (SCI) have different features with regard to neurological characteristics after injury. Recent large-scale longitudinal population-based studies showed that individuals with SCI are at a higher risk of developing dementia than non-SCI patients, indicating that SCI is a potential risk factor for dementia. Aging is known to potentiate inflammation and neurodegeneration at the injured site leading to impaired recovery from SCI. However, no research has been aimed at studying the mechanisms of SCI-mediated cognitive impairment in the elderly. The present study examined neurobehavioral and molecular changes in the brain and the underlying mechanisms associated with brain dysfunction in aged C57BL/6 male mice using a contusion SCI model. At 2 months post-injury, aged mice displayed worse performance in locomotor, cognitive and depressive-like behavioral tests compared to young adult animals. Histopathology in injured spinal cord tissue was exacerbated in aged SCI mice. In the brain, transcriptomic analysis with NanoString neuropathology panel identified activated microglia and dysregulated autophagy as the most significantly altered pathways by both age and injury. These findings were further validated by flow cytometry, which demonstrated increased myeloid and lymphocytes infiltration at both the injured site and brain of aged mice. Moreover, SCI in aged mice altered microglial function and dysregulated autophagy in microglia, resulting in worsened neurodegeneration. Taken together, our data indicate that old age exacerbates neuropathological changes in both the injured spinal cord and remote brain regions leading to poorer functional outcomes, at least in part, through altered inflammation and autophagy function.
PURPOSE:A remedy, containing human erythropoietin as an active constituent and useful as a remedy for malignant tumorous anemia. CONSTITUTION:A remedy containing human erythropoietin as an active constituent. The erythropoietin (hereinafter abbreviated to EPO) is a glycoprotein mainly produced in the kidney and known as a humoral hematopoietic factor having action of affecting erythroblastic stem cells present in marrow to promote the differentiation to erythrocytic cells, but is found to be effective for treating anemia in animals with cancer. The human EPO can be obtained by various means and examples thereof include methods of purification from human urine, gene expression of a gene coding amino acid sequence of the human EPO in a host cell, e.g. Escherichia coli, yeast, Chinese hamster, ovarian cell, COS cell, etc. The remedy is normally administered by a method for administering the human EPO pharmaceutical containing 0.1-500mug EPO per adult 1-7times/ week.
The present invention relates to a system for injecting vitamin E, a vitamin E derivative, or a mixture thereof into the human skin. The system stably impregnates the human skin with vitamin E, a vitamin E derivative, or a mixture thereof, and effectively delivers the vitamin E, a vitamin E derivative, or a mixture thereof into the human skin. Accordingly, the vitamin E, a vitamin E derivative, or a mixture thereof can show an excellent effect. The system is a microneedle including vitamin E, a vitamin E derivative, or a mixture thereof. Furthermore, according to the present invention, provided is a method for injecting vitamin E, a vitamin E derivative, or a mixture thereof into the human skin. The method is characterized by using the microneedle. The vitamin E, a vitamin E derivative, or a mixture thereof is included in a content of 0.001-20 wt% with respect to the total weight of the microneedle.
INTRODUCTION: Increased albuminuria is associated with elevated mortality. Urine albumin (U-ALB) above 20 mg/L or albumin-to-creatinine ratio (U-ACR) of 3 g/mol are indicative of moderately increased albuminuria. Due to limited standardization among U-ALB methods, diagnosis of increased albuminuria might prove difficult.
MATERIALS AND METHODS: Data from Equalis's external quality assessment scheme for low U-ALB levels during 2005-2023 were categorized according to manufacturer and divided into central laboratory (CLAB) and point-of-care testing (POCT) methods. Manufacturer median values were compared to total group mean consensus values and manufacturer CV% was compared at different U-ALB levels.
RESULTS: CLAB was generally closer to consensus values and had lower CV% than POCT at U-ALB levels around 20 mg/L. For CLAB, Roche methods were approximately equal to consensus U-ALB, Abbott 4 % above, and Siemens 5 % below. For POCT, HemoCue was 1 % below, Siemens 7 % above, and Abbott 8 % below. For U-Creatinine, all manufacturers generally had a good agreement differing on average by 1-4 % from consensus.
CONCLUSIONS: Although U-ALB methods generally meet The National Kidney Disease Education Program (NKDEP) recommendations of method bias less than 13 % and imprecision less than 30 %, differences among manufacturers have increased over the last years, with 2023 showing the largest differences between methods. This highlights the need for guidelines for albuminuria and ACR to take method differences into consideration, but also for implementation of suitable urine reference materials.
The current body of literature surrounding ankyloglossia and speed delay is mixed. The literature base is riddled with retrospective reviews, poor descriptions of surgical intervention, and the lack of standardized grading schemes with respect to articulation. Furthermore, the candidacy for intervention in these instances only involves children with anterior tongue tie. There is a complete lack of investigation surrounding the impact of posterior tongue tie on articulation.

The other area that has inadequately been studied is the impact ankyloglossia has on myofunctional outcomes. There are data now that demonstrate how ankyloglossia is correlated with a vaulted palate and has long term orthodontic consequences. This study aims to demonstrate how release of posterior tongue tie improves lingual strength and posture.
Vardenafil is available in 10 mg orally disintegrating tablets. Vardenafil orally disintegrating tabletis not interchangeable with vardenafil 10 mg film-coated tablets (LEVITRA). Vardenafil orally disintegrating tabletprovides higher systemic exposure compared to vardenafil 10 mg film-coated tablets (LEVITRA). [See Clinical Pharmacology (12.3).] 

Vardenafil orally disintegrating tablet should be taken orally, as needed, approximately 60 minutes before sexual activity. The maximum dosing frequency is one Vardenafil orally disintegrating tablet per day. Sexual stimulation is required for a response to treatment.

Vardenafil orally disintegrating tabletshould be placed on the tongue where it will disintegrate. The tablet should   
be taken without liquid. It should be taken immediately upon removal from the blister. 

Those patients who require a lower or higher dose of vardenafil need to be prescribed vardenafil film-coated tablets [see Patient Counseling Information (17)] .
FIELD: food industry. ^ SUBSTANCE: invention relates to therapy and prevention of obesity and may be used for reduction of body weight with both humans and animals. The mammal body weight reduction method envisages addition of a biologically active substances concentrate produced of aspen wood by way of water extraction to the basic ration. For mice the food additive efficient quantity is 0.43-1.71 mg of dry substance of the aspen biologically active substances concentrate (administered daily in two separate doses during a month) per 1 g of live weight. For humans the food additive efficient quantity is 3.6 mg of dry aspen biologically active substances concentrate (administered daily in two separate doses during a month). ^ EFFECT: invention enables to reduce weight smoothly and without side effects and to maintain a lower body weight achieved through weight loss. ^ 3 cl, 4 tbl
A drug delivery system and methods are provided wherein a therapeutic/diagnostic agent or a component of the immune system is directed to particular cells in a selected organ or a specific site. Such a system can be formed by a photoselective compound generally described as V-M-P-C. V is a vector component suitable to target particular cells in a selected organ or site, where the type of the cell or antigen does not have to be specific to the desired treatment site. M is a marker component that is capable of being targeted by a therapeutic/diagnostic agent or a component of the immune system. P is a photocleavable or photosensitive bond, and C is a cap component rendering M ineffective. C is connected to M by the photocleavable or photosensitive bond. The photoselective compound is administered and marks targets of a certain kind of cell or a specific site. Then radiation of a specific wavelength or wavelength range is applied to the geometric volume that is to be treated, uncapping the M sites in the desired treatment volume. Therapeutic or diagnostic agents can be subsequently or concurrently administered in a form that specifically targets the uncapped sites of M. The therapeutic or diagnostic agent can be a drug, a radioactive compound, a fluorescent compound or a photosensitiser. Additional components, such as multiplier molecules, can also be inserted into the basic V-M-P-C scheme. Moreover, the marker component can be such that after the removal of the cap component, components of the immune system can bind to M and thus concentrate at a desired site. The present invention facilitates the delivery of therapeutic/diagnostic agents or components of the immune system to particular cells in a selected organ or a specific site, and therefore, minimizes the potential harmful effect of the agents to the normal cells in the rest of the body.
ETHNOPHARMACOLOGICAL RELEVANCE: Herb couple Rehmannia glutinosa Libosch and Cornus officinalis Sieb (RC), originated from "Liuwei Dihuang Pill" which recorded in Key to Therapeutics of Children's Diseases. Traditionally, they have been used widely for their ability to nourish yin and energize the kidneys. Our previous study indicated that the RC could protect against adenine induced Chronic kidney disease (CKD) rats. Nevertheless, there is still no clear explanation of the mechanisms by which RC affects renal interstitial fibrosis in CKD rats.
AIM OF THE STUDY: Current Work aims to explore the amelioration and potential mechanism of RC on renal interstitial fibrosis in CKD rats.
MATERIALS AND METHODS: CKD rats were induced by adenine. Two weeks after administration, blood, urine, and kidney tissue were collected for biochemical analysis. Observing the physiological state of rats through the changes of rat body weight and renal index. The pro-inflammatory cytokines were measured by enzyme linked immunosorbent assay (ELISA), while renal tissue damage and fibrosis were assessed with Hematoxylin-eosin staining (H&E) and Masson's trichrome staining. In order to determine the levels of indicators and proteins associated with fibrosis signaling pathways, real time PCR (Rt-PCR), Western blot (WB), and immunofluorescence were employed.
RESULTS: The renal interstitial fibrosis led to impaired cellular functions with increased the levels of Blood Urea Nitrogen (BUN), Urine protein (UP), Interleukin-1β (IL-1β), Interleukin-6 (IL-6), and Tumor Necrosis Factor alpha (TNF-α). and simultaneous up-regulated collagenⅠ(COL-1), fibronection (FN), α-smooth muscle actin (a-SMA), transforming growth factor-β1 (TGF-β1), c-Jun N-terminal kinase (JNK), p38 and extracellular regulated protein kinases (ERK), down-regulated the expression of the E-cadherin proteins. RC notably improved renal dysfunction in CKD rats as indicated by decreases in BUN, UP, and renal index. In addition, consistent with the morphological changes of renal tissue, renal interstitial fibrosis in CKD rats after RC intervention was significantly improved, mainly manifested by a decrease in the positive expression of COL-1, FN, and a-SMA, and increased levels of E-cadherin protein. Meanwhile, RC reduced the classical pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in adenine-induced CKD rats. Additionally, RC administration also down-regulated TGF-β1, JNK, p38 and ERK.
CONCLUSION: In conclusion, RC may reduce inflammation in adenine induced CKD rats, improve extracellular matrix (ECM) components deposition, and diminish epithelial-mesenchymal transition (EMT) marker protein levels. Furthermore, RC intervention significantly reduces the release of inflammatory cytokines and inhibits the TGF-β1/MAPK signaling pathway. Based on the results, RC might be useful in the treatment of adenine induced renal fibrosis.
The present disclosure provides an annular, hollow, wearable device (100) for storing and releasing medicinal materials such as progesterone into cervix of a patient to maintain uterine quiescence by maintaining optimal uterine progesterone level, the device being configured to be placed around the cervical canal of the patient. Non-permeable and elastic outer surface (102) of the device (100) is coated with antibacterial materials. An inner surface (104) of the device is coupled with one or more openings (108) configured to release the medicinal materials from one or more hollow chambers (106) into the patient's cervix. The one or more hollow chambers (106) is covered by the outer surface (102) and the inner surface (104). One or more different thickness inner membranes are enabled to control the flow of the medicinal materials in a predetermined sequence and at a predetermined rate. The device (100) is enabled to fit snugly and is adjustable to a predetermined position using a locking unit (112), configured to close the cervix in case of cervical insufficiency.
The patient population for this study is individuals requiring high-flow polyurethane tunneled dialysis catheters (TDC) for hemodialysis access. The primary objective of this study is to compare outcomes of participants who undergo left internal jugular placement of a split-tip versus a step-tip versus symmetric tip catheter. Participants will be randomized to receive a split-tip, step-tip or symmetric tip catheter in a 1:1:1 ratio. All participants will be followed per their referring physician's standard of care. Information regarding any patient complications will be obtained from Dr. Allon's dialysis patient database (Vascular Access in Hemodialysis Patients, IRB # X980813005). This study will review and compare the complication rate and function of the three catheter designs. There are no studies to our knowledge that compared catheter designs placed specifically via the left internal jugular vein. The investigators hypothesize that because the left internal jugular vein is anatomically more complex than the right one, tunneled dialysis catheters with split-tip design may perform sub-optimally, compared to step-tip and symmetric tip designs, when placed via the left internal jugular vein. If this hypothesis is true, the results of the study may influence future clinical practice and reduce the rates of replacement of catheters placed through the left internal jugular vein, resulting in better patient care and significant cost-savings.
The invention discloses a pantoprazole sodium drug for injection. The pantoprazole sodium drug for injection is prepared by packing the following active components and non-active components in parts by weight in a borosilicate glass bottle, covering the bottle by a rubber plug, combining and sealing. The active components and non-active components in parts by weight are as follows: 0.5-2 parts of pantoprazole sodium, 0-0.1 part of oxalic acid diethylamine disodium, 0-0.1 part of alkali and 0-3 parts of a skeleton agent. A preparation method of the pantoprazole sodium drug for injection comprises the following steps: dispensing liquid, pre-freezing, primarily drying, secondarily drying and post-treating. The neutral borosilicate glass bottle is selected, so that the compatibility of the pantoprazole sodium drug can be obviously improved; the drug quality is improved; the risk of transferring glass corrosion caused by alkaline drug to the drug is reduced; furthermore, the clinical safety of the drug is improved. The preparation method of the pantoprazole sodium drug for injection is simple in process, low in energy consumption, convenient to operate, safe to produce and suitable for industrial large-scale production and application.
1. Technical Result Increase in treatment efficiency. 2. Essence A compound of the formula (1) radicals of which are provided in specification. These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. Said compounds are useful for treating a disease or condition in a mammal in need thereof, wherein the mammal would receive symptomatic relief from the administration of 7 nicotinic acetylcholine receptor agonist. 3. Field of Application Medicine.
PROBLEM TO BE SOLVED: To obtain the subject composition stable for a long period of time and having excellent heat and acid resistances even under a condition of retort treating in an acidic medium and useful as an additive for a health food or a cosmetic by homogenizing a glycolipid by using a glycerol fatty acid ester, a diglycerol fatty acid ester, etc. SOLUTION: This composition is obtained by homogenizing (B) a glycolipid (e.g. glycosyl ceramide) with (A) at least one kind (e.g. triglycerol monooleate) selected from glycerol fatty acid ester, diglycerol fatty acid ester and triglycerol fatty acid ester. Preferably, the composition is obtained by adding 100 pts.wt. of liposoluble component of the component B or glycolipid-containing natural substance and 1-1,000 pts.wt. of the component A to water or an alcohol and homogenizing by a homogenizer, etc. The composition is useful as an adding material for a drink such as a sports drink, a fruits drink or a lactic acid bacteria drink, or a food such as bread, a cracker or a jelly.
Micro-LiNiCoMnO2 (MNCM), a cathode material with highest market share, has increasing demand with the growth of lithium battery industry. However, whether MNCM exposure brings adverse effects to workers remains unclear. This study aimed to explore the association between MNCM exposure with systemic inflammation and cardiac function. A cross-sectional study of 347 workers was undertaken from the MNCM production industry in Guangdong province, China in 2020. Metals in urine were measured using ICP-MS. The associations between metals, systemic inflammation, and cardiac function were appraised using a linear or logistic regression model. Bayesian kernel machine regression (BKMR) and generalized weighted quantile sum (gWQS) models were used to explore mixed metal exposures. The analysis of interaction and mediation was adopted to assess the role of inflammation in the relation between urinary metals and cardiac function. We observed that the levels of lithium (Li) and cobalt (Co) were positively associated with systemic inflammation and heart rate. The amount of Co contributed the highest weight on the increased systemic immune-inflammation index (SII) (59.8%), the system inflammation response index (SIRI) (44.3%), and heart rate (65.0%). Based on the mediation analysis, we estimated that SII mediated 32.3% and 20.9% of the associations between Li and Co with heart rate, and SIRI mediated 44.6% and 22.2% of the associations between Li and Co with heart rate, respectively. This study demonstrated for the first time that MNCM exposure increased the risk of workers' systemic inflammation and elevated heart rate, which were contributed by the excessive Li and Co exposure. Additionally, it indicates that systemic inflammation was a major mediator of the associations of Li and Co with cardiac function in MNCM production workers.
A 4-year-old female spayed French bulldog was presented with a 2-day history of neck pain and left thoracic limb lameness with no neurological deficits. A computed tomography (CT) examination showed a left foraminal T1-2 disc extrusion. Surgical management was performed using a left lateral approach to the vertebral column with a scapular osteotomy. A T1-2 mini-hemilaminectomy was performed. The scapular osteotomy was stabilized with two 2.4-mm locking compression plates. The postoperative CT and radiographic examinations showed adequate decompression of the T1-2 foramen and good reduction in the scapular osteotomy. The dog was able to walk the following day. At the 1-month follow-up, the dog had no neck pain but persistent slight left thoracic limb lameness. Ten months postoperatively, a CT scan showed no abnormalities at the surgical site, and the dog had no neurological deficits nor lameness. The aim of this case report was to describe a new lateral approach to T1-2 intervertebral space.
The invention discloses a buckwheat husk flavonoid extractive. The extractive is prepared after steps: buckwheat husks are subjected to drying and crushing, water is added, high temperature high pressure extraction is carried out, filtering is carried out, and filtrate macroporous resin dynamic adsorption-elution is carried out. Experiments prove that after mice with II type diabetes are administrated with the extractive, a hypoglycemic effect is achieved. The level of INS in serum of mice with II type diabetes can be raised substantially, and the facts are proved that the buckwheat husk flavonoid extractive has an obvious function to pancreatic beta cells and promotes secretion of insulin to a normal level. The buckwheat husk flavonoid extractive shows strong inhibition activity to a DPP4 enzyme, and the effect is better than effects of rutin, quercetin and isoquercitrin, the buckwheat husk flavonoid extractive is a mixture, which illustrates that the buckwheat husk flavonoid extractive contains other effective components besides flavonoid compounds and can be employed as a natural DPP4 inhibitor. Buckwheat husks provide a new raw material source for auxiliary medicines preventing the II type diabetes, and the purified buckwheat husk flavonoid extractive can become a novel, safe and natural target medicine treating II type diabetes.
The invention relates to a novel approach for the diagnosis and therapy of renal cell carcinoma, and other renal tumors, for example Wilms' tumor or other tumors not originating from the kidney or non-malignant kidney pathologies. The areas of application of the invention include the field of medicine and the pharmaceutical industry but also basic biology. The aim of the invention is to provide novel forms of treatment which are urgently required regarding the present state-of-the-art in treatment of renal carcinoma and other cancers. It was discovered that the Nbk protein which is highly expressed in normal renal tissue, is either not expressed at all or only weakly expressed in the tumor tissue. The protein expression and the loss of Nbk was examined in renal cell carcinoma samples by the use of immunohistochemistry, PCR strategies, mutation and deletion analyses. The inventive method for diagnosis is characterized by that the Nbk protein concentration or the Nbk RNA quantity or Nbk mutation or deletion or Nbk gene modification, preferentially methylation, in tissue-derived material is determined. The inventive agent for the therapy of the renal carcinoma and other cells with low Nbk protein or RNA expression is that Nbk expression is increased and directly initiates the therapeutic effect in these cells. The implementation of a novel agent in non-tumorous kidney diseases is based on the inhibition of Nbk RNA or protein expression or Nbk activity.